Taken together, our results indicated that SPHK1 might play a pivotal role in the TME and that an SPHK1 inhibitor has the potential to facilitate an antitumor response by downregulating PD-L1 on melanoma cells and thereby reversing the dysfunctional status of tumor-infiltrating CTLs. The gene discussed is SPHK1; the disease is neoplasm.